



Food and Drug Administration
Rockville, MD 20857

June 10, 2004

James N. Czaban
Heller Ehrman White & McAuliffe LLP
1666 K Street, N.W.
Washington, DC 20006

Dear Mr. Czaban:

Your petition on behalf of Teva Pharmaceuticals USA Inc. requesting the Food and Drug Administration to take immediate action to enforce FDA's existing regulations and establish policy in order to prevent Pfizer Inc. from marketing a generic version of it Accupril (quinapril) drug products until after expiration of Teva's 180-day exclusivity period for generic quinapril products was received by this office on 06/10/2004. It was assigned docket number 2004P-0261/CP1 and it was filed on 06/10/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

